Randomized placebo-controlled trial of the bradykinin B2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial

Cicardi, 1998, Pathogenetic and clinical aspects of C1 inhibitor deficiency, Immunobiology, 199, 366, 10.1016/S0171-2985(98)80033-8

Nussberger, 1998, Plasma bradykinin in angio-oedema, Lancet, 351, 1693, 10.1016/S0140-6736(97)09137-X

Cugno, 2003, Bradykinin and the pathophysiology of angioedema, Int Immunopharmacol, 3, 311, 10.1016/S1567-5769(02)00162-5

Bork, 2007, Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant), J Allergy Clin Immunol, 119, 1497, 10.1016/j.jaci.2007.02.012

Nussberger, 1999, Local bradykinin generation in hereditary angioedema, J Allergy Clin Immunol, 104, 1321, 10.1016/S0091-6749(99)70030-8

Khan, 2011, Hereditary angioedema: historical aspects, classification, pathophysiology, clinical presentation, and laboratory diagnosis, Allergy Asthma Proc, 32, 1, 10.2500/aap.2011.32.3411

Zuraw, 2010, Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema, J Allergy Clin Immunol, 126, 821, 10.1016/j.jaci.2010.07.021

Levy, 2006, The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema, Expert Opin Invest Drugs, 15, 1077, 10.1517/13543784.15.9.1077

Cicardi, 2010, Icatibant, a novel bradykinin B2 receptor antagonist, is effective in the treatment of acute attacks in patients with hereditary angioedema, N Engl J Med, 363, 532, 10.1056/NEJMoa0906393